Inducing humoral immune responses against regulatory T cells by Foxp3-Fc(IgG) fusion protein

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

Volumn 34, Issue 6, 2015, Pages 381-385

  Niri, Neda Mousavi ^a   Hadjati, Jamshid ^b   Sadat, Mahdi ^c   Memarnejadian, Arash ^c   Aghasadeghi, Mohammadreza ^c   Akbarzadeh, Abolfazl ^a   Zarghami, Nosratollah ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; FC RECEPTOR; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; NITRILOTRIACETATE NICKEL; RECOMBINANT PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR FOXP3 IMMUNOGLOBULIN G1 FC FRAGMENT FUSION PROTEIN; UNCLASSIFIED DRUG; CANCER VACCINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; HYBRID PROTEIN; IMMUNOGLOBULIN G;

AFFINITY CHROMATOGRAPHY; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ARTICLE; B LYMPHOCYTE; BACTERIAL STRAIN; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; HOST CELL; HUMORAL IMMUNITY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; VACCINATION; WESTERN BLOTTING; ADMINISTRATION AND DOSAGE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; HELPER CELL; IMMUNOLOGY; LYMPHOCYTE DEPLETION; METABOLISM; MOLECULAR CLONING; PLASMID;

ANIMALS; B-LYMPHOCYTES; CANCER VACCINES; CLONING, MOLECULAR; ESCHERICHIA COLI; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; IMMUNITY, HUMORAL; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED C57BL; PLASMIDS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY; VACCINATION; VACCINES, DNA;

EID: 84951868448     PISSN: None     EISSN: 21679436     Source Type: Journal    
DOI: 10.1089/mab.2015.0048     Document Type: Article

References (20)

1. Vergati M, Schlom J, and Tsang KY. The consequence of immune suppressive cells in the use of therapeutic cancer vaccines and their importance in immune monitoring. J Biomed Biotechnol 2011; 182413
2. Nizar S, Copier J, Meyer B, Bodman-Smith M, Galustian C, Kumar D, and Dalgleish A. T-regulatory cell modulation: the future of cancer immunotherapy? Br J Cancer 2009; 100(11): 1697-1703
3. Generali D, Bates G, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Dogliotti L, Banham AH, Harris AL, Bottini A, and Fox SB. Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients. Clin Cancer Res 2009; 15(3): 1046-1051
4. Nair S, Boczkowski D, Fassnacht M, Pisetsky D, and Gilboa E. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. Cancer Res 2007; 67(1): 371-380
5. Beyer M, Kochanek M, Darabi K, Popov A, Jensen M, Endl E, Knolle PA, Thomas RK, von Bergwelt-Baildon M, Debey S, Hallek M, and Schultze JL. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106(6): 2018-2025
6. Javia LR, and Rosenberg SA. CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother 2003; 26(1): 85-93
7. Motta M, Rassenti L, Shelvin BJ, Lerner S, Kipps TJ, Keating MJ, and Wierda WG. Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemia. Leukemia 2005; 19(10): 1788-1793
8. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, and June CH. Regulatory CD4(+)CD25(+) T cells in tumors from patients with earlystage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001; 61(12): 4766-4772
9. Morse MA, Hobeika AC, Osada T, Serra D, Niedzwiecki D, Lyerly HK, and Clay TM. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. Blood 2008; 112(3): 610-618
10. Zizzari IG, Veglia F, Taurino F, Rahimi H, Quaglino E, Belleudi F, Riccardo F, Antonilli M, Napoletano C, Bellati F, Benedetti-Panici P, Torrisi MR, Frati L, Nuti M, and Rughetti A. HER2-based recombinant immunogen to target DCs through FcgammaRs for cancer immunotherapy. J Mol Med 2011; 89(12): 1231-1240
11. You Z, Huang X, Hester J, Toh HC, and Chen SY. Targeting dendritic cells to enhance DNA vaccine potency. Cancer Res 2001; 61(9): 3704-3711
12. Mousavi Niri N, Memarnejadian A, Hadjati J, Aghasadeghi M, Shokri M, Akbarzadeh A, and Zarghami N. Construction and production of Foxp3-Fc(IgG) DNA vaccine/fusion protein. Avicenna J Med Biotech (in press
13. Crowe J, Masone BS, and Ribbe J. One-step purification of recombinant proteins with the 6xHis tag and Ni-NTA resin. Methods Mol Biol 1996; 58: 491-510
14. Hainfeld JF, Liu W, Halsey CM, Freimuth P, and Powell RD. Ni-NTA-gold clusters target His-tagged proteins. J Struc Biol 1999; 127(2): 185-198
15. Yazdanian M, Memarnejadian A, Mahdavi M, Motevalli F, Sadat SM, Vahabpour R, Khanahmad H, Soleimanjahi H, Budkowska A, and Roohvand F. Evaluation of cellular responses for a chimeric HBsAg-HCV core DNA vaccine in BALB/c mice. Adv Biomed Res 2015; 4: 13
16. Memarnejadian A, Roohvand F, Arashkia A, Rafati S, and Shokrgozar MA. Polytope DNA vaccine development against hepatitis C virus: a streamlined approach from in silico design to in vitro and primary in vivo analyses in BALB/c mice. Protein Peptide Lett 2009; 16(7): 842-850
17. Umansky V, and Sevko A. Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation. Cancer Immunol Immunother 2012; 61(2): 275-282
18. Estcourt MJ, McMichael AJ, and Hanke T. DNA vaccines against human immunodeficiency virus type 1. Immunol Rev 2004; 199: 144-155
19. Kim JM, and Ashkenazi A. Fcgamma receptors enable anticancer action of proapoptotic and immune-modulatory antibodies. J Exp Med 2013; 210(9): 1647-1651
20. Guyre PM, Graziano RF, Goldstein J, Wallace PK, Morganelli PM, Wardwell K, and Howell AL. Increased potency of Fc-receptor-targeted antigens. Cancer Immunol Immunother 1997; 45(3-4): 146-148